Market Overview

UPDATE: Jefferies Lowers PT on AbbVie on Attractive Entry Point Potential

Share:
Related
Benzinga's M&A Chatter for Monday July 27, 2015
With The Teva Money, Allergan Could Engage In 'Large M&A' Next: Evercore ISI
Premarket Biotech Digest: Gilead HIV, Eliquis Trial Errors, Clinical Trial Phases (Seeking Alpha)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on AbbVie (NYSE: ABBV), but lowered the price target from $54.00 to $51.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

AbbVie closed on Thursday at $43.04.

Latest Ratings for ABBV

DateFirmActionFromTo
Jul 2015Deutsche BankMaintainsBuy
Jul 2015SunTrust Robinson HumphreyInitiates Coverage onBuy
Jun 2015Piper JaffrayInitiates Coverage onOverweight

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABBV)

Get Benzinga's Newsletters